Motif Bio PLC New Data on Iclaprim (8018N)
31 Ottobre 2016 - 8:00AM
UK Regulatory
TIDMMTFB
RNS Number : 8018N
Motif Bio PLC
31 October 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION
This announcement contains inside information.
Motif Bio plc
("Motif Bio" or the "Company")
New data on iclaprim released at IDWeek 2016
Iclaprim shown to be highly potent against SSSI and HABP
clinical isolates
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that new data were presented on the antimicrobial activity of its
lead antibiotic, iclaprim, against recent clinical samples of
Gram-positive bacteria, including multidrug resistant isolates,
gathered from around the World.
The new data were presented during IDWeek 2016 in New Orleans
and provided details of a global in vitro microbiological
surveillance programme testing 1636 strains of bacteria associated
with Hospital Associated Bacterial Pneumonia ("HABP") and Skin and
Skin Structure Infections ("SSSI") collected from patients in the
United States, Europe, Latin America and the Asia Pacific. These
bacteria were tested against iclaprim and a range of other standard
of care antibiotics.
As demonstrated in the Table below, the results showed that
iclaprim was highly potent against strains of Staphylococcus
aureus, beta-hemolytic streptococci, and Streptococcus pneumoniae
associated with clinical SSSI and HABP isolates taken globally
during 2012 to 2014.
(MIC50/90 mg/L)
---------------- ------ ------------------------------------------------
Pathogen n Iclaprim Vancomycin Linezolid Daptomycin
---------------- ------ ---------- ----------- ---------- -----------
Staphylococcus
aureus 1,178 0.06/0.12 1/1 1/1 0.25/0.5
---------------- ------ ---------- ----------- ---------- -----------
MRSA 582 0.06/0.5 1/1 1/1 0.25/0.5
---------------- ------ ---------- ----------- ---------- -----------
MSSA 596 0.06/0.12 1/1 1/1 0.25/0.5
---------------- ------ ---------- ----------- ---------- -----------
Beta-hemolytic
streptococci 199 0.06/0.25 0.25/0.5 1/1 0.12/0.25
---------------- ------ ---------- ----------- ---------- -----------
Streptococcus
pneumoniae 259 0.06/2 0.25/0.5 1/1 0.12/0.25
---------------- ------ ---------- ----------- ---------- -----------
Total 1636
---------------- ------ ---------- ----------- ---------- -----------
The full poster can be down loaded at:
https://idsa.confex.com/idsa/2016/webprogram/Paper56742.html
A registration statement relating to the Company's securities
has been filed with the SEC, but has not yet become effective. Such
securities may not be sold, nor may offers to buy the securities be
accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or a solicitation of an offer to buy any securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
For further information please contact:
Motif Bio plc info@motifbio.com
Richard Morgan (Chairman)
Graham Lumsden (Chief
Executive Officer)
Zeus Capital Limited
(NOMAD & BROKER)
Phil Walker/Giles Balleny
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners
Limited (BROKER)
Patrick Claridge/ David
Hignell
John Howes/ Rob Rees
(Broking) +44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalized patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), which
is often caused by MRSA (methicillin resistant Staphylococcus
aureus). We are currently enrolling and dosing patients in two
global Phase 3 clinical trials (Revive 1 and Revive 2) with an
intravenous formulation of iclaprim, for the treatment of ABSSSI.
Patient enrolment for REVIVE-1 has exceeded projections and data
readout is now expected in the second quarter of 2017, rather than
the second half of 2017, as previously stated. REVIVE-2 remains on
track with data readout continuing to be expected in the second
half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESFEMFAAFMSESS
(END) Dow Jones Newswires
October 31, 2016 03:00 ET (07:00 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024